The global clinical oncology next generation sequencing market size was estimated at USD 482.3 million in 2024 and is projected to reach USD 1.93 billion by 2033, growing at a CAGR of 16.77% from 2025 to 2033. The key drivers responsible for the growth of the clinical oncology next generation sequencing (NGS) industry are increasing technological advancements, growing competition among players, increasing healthcare spending, and the rise in the prevalence of cancer.
In addition, augmenting research & development activities to invent solutions is expected to fuel the market growth over the forecast period.
This product will be delivered within 2 business days.
In addition, augmenting research & development activities to invent solutions is expected to fuel the market growth over the forecast period.
Global Clinical Oncology Next Generation Sequencing Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and analyzes the latest industry trends in each sub-segment from 2021 to 2033. Grand View Research has segmented the global clinical oncology next generation sequencing market report based on workflow, technology, application, end use, and region.Workflow Outlook (Revenue, USD Million, 2021 - 2033)
- NGS Pre-Sequencing
- NGS Sequencing
- NGS Data Analysis
Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Whole Genome Sequencing
- Whole Exome Sequencing
- Targeted Sequencing & Resequencing
Application Outlook (Revenue, USD Million, 2021 - 2033)
- Screening
- Sporadic Cancer
- Inherited Cancer
- Companion Diagnostics
- Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Clinics
- Laboratories
Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definitions
1.2.1. Workflow Segment
1.2.2. Technology Segment
1.2.3. Application Segment
1.2.4. End Use Segment
1.3. Information analysis
1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
1.2. Market Definitions
1.2.1. Workflow Segment
1.2.2. Technology Segment
1.2.3. Application Segment
1.2.4. End Use Segment
1.3. Information analysis
1.3.1. Market formulation & data visualization
1.4. Data validation & publishing
1.5. Information Procurement
1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segmental Snapshot
2.3. Competitive Landscape Snapshot
2.2. Segmental Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, and Scope
3.1. Market Lineage
3.1.1. Parent Market Analysis
3.1.2. Ancillary Market Analysis
3.2. Clinical Oncology NGS Market- Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTLE Analysis
3.3.3. COVID-19 Impact Analysis
3.1.1. Parent Market Analysis
3.1.2. Ancillary Market Analysis
3.2. Clinical Oncology NGS Market- Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTLE Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Clinical Oncology NGS Market: Workflow Business Analysis
4.1. Workflow Segment Dashboard
4.2. Global Clinical Oncology NGS Market Workflow Movement Analysis, 2024 & 2033
4.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Million)
4.4. NGS Pre-Sequencing
4.4.1. Global NGS Pre-Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
4.5. NGS Sequencing
4.5.1. Global NGS Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. NGS Data Analysis
4.6.1. Global NGS Data Analysis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
4.2. Global Clinical Oncology NGS Market Workflow Movement Analysis, 2024 & 2033
4.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Million)
4.4. NGS Pre-Sequencing
4.4.1. Global NGS Pre-Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
4.5. NGS Sequencing
4.5.1. Global NGS Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. NGS Data Analysis
4.6.1. Global NGS Data Analysis Market Estimates And Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Clinical Oncology NGS Market: Technology Business Analysis
5.1. Technology Segment Dashboard
5.2. Global Clinical Oncology NGS Market Technology Movement Analysis, 2024 & 2033
5.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
5.4. Whole Genome Sequencing
5.4.1. Global Whole Genome Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
5.5. Whole Exome Sequencing
5.5.1. Global Whole Exome Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
5.6. Targeted Sequencing & Resequencing
5.6.1. Global Targeted Sequencing & Resequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
5.2. Global Clinical Oncology NGS Market Technology Movement Analysis, 2024 & 2033
5.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
5.4. Whole Genome Sequencing
5.4.1. Global Whole Genome Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
5.5. Whole Exome Sequencing
5.5.1. Global Whole Exome Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
5.6. Targeted Sequencing & Resequencing
5.6.1. Global Targeted Sequencing & Resequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Clinical Oncology NGS Market: Application Business Analysis
6.1. Application Segment Dashboard
6.2. Global Clinical Oncology NGS Market Application Movement Analysis, 2024 & 2033
6.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
6.4. Screening
6.4.1. Global Screening Market Estimates And Forecasts, 2021 - 2033 (USD Million)
6.5. Companion Diagnostics
6.5.1. Global Companion Diagnostics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
6.5.2. Sporadic Cancer
6.5.2.1. Global Sporadic Cancer Market Estimates And Forecasts, 2021 - 2033 (USD Million)
6.5.3. Inherited Cancer
6.5.3.1. Global Inherited Cancer Market Estimates And Forecasts, 2021 - 2033 (USD Million)
6.6. Others
6.6.1. Global Others Market Estimates And Forecasts, 2021 - 2033 (USD Million)
6.2. Global Clinical Oncology NGS Market Application Movement Analysis, 2024 & 2033
6.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
6.4. Screening
6.4.1. Global Screening Market Estimates And Forecasts, 2021 - 2033 (USD Million)
6.5. Companion Diagnostics
6.5.1. Global Companion Diagnostics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
6.5.2. Sporadic Cancer
6.5.2.1. Global Sporadic Cancer Market Estimates And Forecasts, 2021 - 2033 (USD Million)
6.5.3. Inherited Cancer
6.5.3.1. Global Inherited Cancer Market Estimates And Forecasts, 2021 - 2033 (USD Million)
6.6. Others
6.6.1. Global Others Market Estimates And Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Clinical Oncology NGS Market: End Use Business Analysis
7.1. End Use Segment Dashboard
7.2. Global Clinical Oncology NGS Market End Use Movement Analysis, 2024 & 2033
7.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
7.4. Clinics
7.4.1. Global Clinics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
7.5. Hospitals
7.5.1. Global Hospitals Market Estimates And Forecasts, 2021 - 2033 (USD Million)
7.6. Laboratories
7.6.1. Global Laboratories Market Estimates And Forecasts, 2021 - 2033 (USD Million)
7.2. Global Clinical Oncology NGS Market End Use Movement Analysis, 2024 & 2033
7.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
7.4. Clinics
7.4.1. Global Clinics Market Estimates And Forecasts, 2021 - 2033 (USD Million)
7.5. Hospitals
7.5.1. Global Hospitals Market Estimates And Forecasts, 2021 - 2033 (USD Million)
7.6. Laboratories
7.6.1. Global Laboratories Market Estimates And Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Clinical Oncology NGS Market: Regional Estimates & Trend Analysis by Workflow, Technology, Application, and End Use
8.1. Regional Market Share Analysis, 2024 & 2033
8.2. Regional Market Dashboard
8.3. Market Size, & Forecasts, Trend Analysis, 2021 to 2033:
8.4. North America
8.4.1. North America market estimates and forecasts 2021 to 2033 (USD Million)
8.4.2. U.S.
8.4.2.1. Key country dynamics
8.4.2.2. Competitive scenario
8.4.2.3. Regulatory framework
8.4.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
8.4.3. Canada
8.4.3.1. Key country dynamics
8.4.3.2. Competitive scenario
8.4.3.3. Regulatory framework
8.4.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
8.4.4. Mexico
8.4.4.1. Key country dynamics
8.4.4.2. Competitive scenario
8.4.4.3. Regulatory framework
8.4.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
8.5. Europe
8.5.1. Europe market estimates and forecasts 2021 to 2033 (USD Million)
8.5.2. UK
8.5.2.1. Key country dynamics
8.5.2.2. Competitive scenario
8.5.2.3. Regulatory framework
8.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
8.5.3. Germany
8.5.3.1. Key country dynamics
8.5.3.2. Competitive scenario
8.5.3.3. Regulatory framework
8.5.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
8.5.4. France
8.5.4.1. Key country dynamics
8.5.4.2. Competitive scenario
8.5.4.3. Regulatory framework
8.5.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
8.5.5. Italy
8.5.5.1. Key country dynamics
8.5.5.2. Competitive scenario
8.5.5.3. Regulatory framework
8.5.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
8.5.6. Spain
8.5.6.1. Key country dynamics
8.5.6.2. Competitive scenario
8.5.6.3. Regulatory framework
8.5.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
8.5.7. Denmark
8.5.7.1. Key country dynamics
8.5.7.2. Competitive scenario
8.5.7.3. Regulatory framework
8.5.7.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
8.5.8. Sweden
8.5.8.1. Key country dynamics
8.5.8.2. Competitive scenario
8.5.8.3. Regulatory framework
8.5.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
8.5.9. Norway
8.5.9.1. Key country dynamics
8.5.9.2. Competitive scenario
8.5.9.3. Regulatory framework
8.5.9.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
8.6.2. Japan
8.6.2.1. Key country dynamics
8.6.2.2. Competitive scenario
8.6.2.3. Regulatory framework
8.6.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
8.6.3. China
8.6.3.1. Key country dynamics
8.6.3.2. Competitive scenario
8.6.3.3. Regulatory framework
8.6.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
8.6.4. India
8.6.4.1. Key country dynamics
8.6.4.2. Competitive scenario
8.6.4.3. Regulatory framework
8.6.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
8.6.5. Australia
8.6.5.1. Key country dynamics
8.6.5.2. Competitive scenario
8.6.5.3. Regulatory framework
8.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
8.6.6. South Korea
8.6.6.1. Key country dynamics
8.6.6.2. Competitive scenario
8.6.6.3. Regulatory framework
8.6.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
8.6.7. Thailand
8.6.7.1. Key country dynamics
8.6.7.2. Competitive scenario
8.6.7.3. Regulatory framework
8.6.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
8.7. Latin America
8.7.1. Latin America market estimates and forecasts 2021 to 2033 (USD Million)
8.7.2. Brazil
8.7.2.1. Key country dynamics
8.7.2.2. Competitive scenario
8.7.2.3. Regulatory framework
8.7.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
8.7.3. Argentina
8.7.3.1. Key country dynamics
8.7.3.2. Competitive scenario
8.7.3.3. Regulatory framework
8.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
8.8. MEA
8.8.1. MEA market estimates and forecasts 2021 to 2033 (USD Million)
8.8.2. South Africa
8.8.2.1. Key country dynamics
8.8.2.2. Competitive scenario
8.8.2.3. Regulatory framework
8.8.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key country dynamics
8.8.3.2. Competitive scenario
8.8.3.3. Regulatory framework
8.8.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
8.8.4. UAE
8.8.4.1. Key country dynamics
8.8.4.2. Competitive scenario
8.8.4.3. Regulatory framework
8.8.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key country dynamics
8.8.5.2. Competitive scenario
8.8.5.3. Regulatory framework
8.8.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
8.2. Regional Market Dashboard
8.3. Market Size, & Forecasts, Trend Analysis, 2021 to 2033:
8.4. North America
8.4.1. North America market estimates and forecasts 2021 to 2033 (USD Million)
8.4.2. U.S.
8.4.2.1. Key country dynamics
8.4.2.2. Competitive scenario
8.4.2.3. Regulatory framework
8.4.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
8.4.3. Canada
8.4.3.1. Key country dynamics
8.4.3.2. Competitive scenario
8.4.3.3. Regulatory framework
8.4.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
8.4.4. Mexico
8.4.4.1. Key country dynamics
8.4.4.2. Competitive scenario
8.4.4.3. Regulatory framework
8.4.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
8.5. Europe
8.5.1. Europe market estimates and forecasts 2021 to 2033 (USD Million)
8.5.2. UK
8.5.2.1. Key country dynamics
8.5.2.2. Competitive scenario
8.5.2.3. Regulatory framework
8.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
8.5.3. Germany
8.5.3.1. Key country dynamics
8.5.3.2. Competitive scenario
8.5.3.3. Regulatory framework
8.5.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
8.5.4. France
8.5.4.1. Key country dynamics
8.5.4.2. Competitive scenario
8.5.4.3. Regulatory framework
8.5.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
8.5.5. Italy
8.5.5.1. Key country dynamics
8.5.5.2. Competitive scenario
8.5.5.3. Regulatory framework
8.5.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
8.5.6. Spain
8.5.6.1. Key country dynamics
8.5.6.2. Competitive scenario
8.5.6.3. Regulatory framework
8.5.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
8.5.7. Denmark
8.5.7.1. Key country dynamics
8.5.7.2. Competitive scenario
8.5.7.3. Regulatory framework
8.5.7.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
8.5.8. Sweden
8.5.8.1. Key country dynamics
8.5.8.2. Competitive scenario
8.5.8.3. Regulatory framework
8.5.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
8.5.9. Norway
8.5.9.1. Key country dynamics
8.5.9.2. Competitive scenario
8.5.9.3. Regulatory framework
8.5.9.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million)
8.6.2. Japan
8.6.2.1. Key country dynamics
8.6.2.2. Competitive scenario
8.6.2.3. Regulatory framework
8.6.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
8.6.3. China
8.6.3.1. Key country dynamics
8.6.3.2. Competitive scenario
8.6.3.3. Regulatory framework
8.6.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
8.6.4. India
8.6.4.1. Key country dynamics
8.6.4.2. Competitive scenario
8.6.4.3. Regulatory framework
8.6.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
8.6.5. Australia
8.6.5.1. Key country dynamics
8.6.5.2. Competitive scenario
8.6.5.3. Regulatory framework
8.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
8.6.6. South Korea
8.6.6.1. Key country dynamics
8.6.6.2. Competitive scenario
8.6.6.3. Regulatory framework
8.6.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
8.6.7. Thailand
8.6.7.1. Key country dynamics
8.6.7.2. Competitive scenario
8.6.7.3. Regulatory framework
8.6.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
8.7. Latin America
8.7.1. Latin America market estimates and forecasts 2021 to 2033 (USD Million)
8.7.2. Brazil
8.7.2.1. Key country dynamics
8.7.2.2. Competitive scenario
8.7.2.3. Regulatory framework
8.7.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
8.7.3. Argentina
8.7.3.1. Key country dynamics
8.7.3.2. Competitive scenario
8.7.3.3. Regulatory framework
8.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
8.8. MEA
8.8.1. MEA market estimates and forecasts 2021 to 2033 (USD Million)
8.8.2. South Africa
8.8.2.1. Key country dynamics
8.8.2.2. Competitive scenario
8.8.2.3. Regulatory framework
8.8.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key country dynamics
8.8.3.2. Competitive scenario
8.8.3.3. Regulatory framework
8.8.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
8.8.4. UAE
8.8.4.1. Key country dynamics
8.8.4.2. Competitive scenario
8.8.4.3. Regulatory framework
8.8.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key country dynamics
8.8.5.2. Competitive scenario
8.8.5.3. Regulatory framework
8.8.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company/Competition Categorization
9.2. Strategy Mapping
9.3. Company Market Position Analysis, 2024
9.4. Company Profiles/Listing
9.4.1. Thermo Fisher Scientific Inc.
9.4.1.1. Company overview
9.4.1.2. Financial performance
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.4.2. Illumina, Inc.
9.4.2.1. Company overview
9.4.2.2. Financial performance
9.4.2.3. Product benchmarking
9.4.2.4. Strategic initiatives
9.4.3. Myriad Genetics
9.4.3.1. Company overview
9.4.3.2. Financial performance
9.4.3.3. Product benchmarking
9.4.3.4. Strategic initiatives
9.4.4. F. Hoffmann-La Roche Ltd.
9.4.4.1. Company overview
9.4.4.2. Financial performance
9.4.4.3. Product benchmarking
9.4.4.4. Strategic initiatives
9.4.5. Agilent Technologies, Inc.
9.4.5.1. Company overview
9.4.5.2. Financial performance
9.4.5.3. Product benchmarking
9.4.5.4. Strategic initiatives
9.4.6. Perkin Elmer
9.4.6.1. Company overview
9.4.6.2. Financial performance
9.4.6.3. Product benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Pacific Bioscience
9.4.7.1. Company overview
9.4.7.2. Financial performance
9.4.7.3. Product benchmarking
9.4.7.4. Strategic initiatives
9.4.8. Oxford Nanopore Technologies Ltd.
9.4.8.1. Company overview
9.4.8.2. Financial performance
9.4.8.3. Product benchmarking
9.4.8.4. Strategic initiatives
9.4.9. Eurofins Scientific S.E.
9.4.9.1. Company overview
9.4.9.2. Financial performance
9.4.9.3. Product benchmarking
9.4.9.4. Strategic initiatives
9.4.10. Qiagen N.V.
9.4.10.1. Company overview
9.4.10.2. Financial performance
9.4.10.3. Product benchmarking
9.4.10.4. Strategic initiatives
9.2. Strategy Mapping
9.3. Company Market Position Analysis, 2024
9.4. Company Profiles/Listing
9.4.1. Thermo Fisher Scientific Inc.
9.4.1.1. Company overview
9.4.1.2. Financial performance
9.4.1.3. Product benchmarking
9.4.1.4. Strategic initiatives
9.4.2. Illumina, Inc.
9.4.2.1. Company overview
9.4.2.2. Financial performance
9.4.2.3. Product benchmarking
9.4.2.4. Strategic initiatives
9.4.3. Myriad Genetics
9.4.3.1. Company overview
9.4.3.2. Financial performance
9.4.3.3. Product benchmarking
9.4.3.4. Strategic initiatives
9.4.4. F. Hoffmann-La Roche Ltd.
9.4.4.1. Company overview
9.4.4.2. Financial performance
9.4.4.3. Product benchmarking
9.4.4.4. Strategic initiatives
9.4.5. Agilent Technologies, Inc.
9.4.5.1. Company overview
9.4.5.2. Financial performance
9.4.5.3. Product benchmarking
9.4.5.4. Strategic initiatives
9.4.6. Perkin Elmer
9.4.6.1. Company overview
9.4.6.2. Financial performance
9.4.6.3. Product benchmarking
9.4.6.4. Strategic initiatives
9.4.7. Pacific Bioscience
9.4.7.1. Company overview
9.4.7.2. Financial performance
9.4.7.3. Product benchmarking
9.4.7.4. Strategic initiatives
9.4.8. Oxford Nanopore Technologies Ltd.
9.4.8.1. Company overview
9.4.8.2. Financial performance
9.4.8.3. Product benchmarking
9.4.8.4. Strategic initiatives
9.4.9. Eurofins Scientific S.E.
9.4.9.1. Company overview
9.4.9.2. Financial performance
9.4.9.3. Product benchmarking
9.4.9.4. Strategic initiatives
9.4.10. Qiagen N.V.
9.4.10.1. Company overview
9.4.10.2. Financial performance
9.4.10.3. Product benchmarking
9.4.10.4. Strategic initiatives
List of Tables
TABLE 1 Global clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 2 Global clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 3 Global clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 4 Global clinical oncology NGS screening market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 5 Global clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 6 North America clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 7 North America clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 8 North America clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 9 North America clinical oncology NGS screening market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 10 North America clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 11 The U.S. clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 12 The U.S. clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 13 The U.S. clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 14 The U.S. clinical oncology NGS screening market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 15 The U.S. clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 16 Canada clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 17 Canada clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 18 Canada clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 19 Canada clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 20 Mexico clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 21 Mexico clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 22 Mexico clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 23 Mexico clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 24 Europe clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 25 Europe clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 26 Europe clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 27 Europe clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 28 Germany clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 29 Germany clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 30 Germany clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 31 Germany clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 32 UK clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 33 UK clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 34 UK clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 35 UK clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 36 France clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 37 France clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 38 France clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 39 France clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 40 Italy clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 41 Italy clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 42 Italy clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 43 Italy clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 44 Spain clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 45 Spain clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 46 Spain clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 47 Spain clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 48 Denmark clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 49 Denmark clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 50 Denmark clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 51 Denmark clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 52 Sweden clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 53 Sweden clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 54 Sweden clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 55 Sweden clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 56 Norway clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 57 Norway clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 58 Norway clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 59 Norway clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 60 Asia Pacific clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 61 Asia Pacific clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 62 Asia Pacific clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 63 Asia Pacific clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 64 Japan clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 65 Japan clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 66 Japan clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 67 Japan clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 68 China clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 69 China clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 70 China clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 71 China clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 72 India clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 73 India clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 74 India clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 75 India clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 76 South Korea clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 77 South Korea clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 78 South Korea clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 79 South Korea clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 80 Australia clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 81 Australia clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 82 Australia clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 83 Australia clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 84 Thailand clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 85 Thailand clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 86 Thailand clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 87 Thailand clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 88 Latin America clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 89 Latin America clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 90 Latin America clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 91 Latin America clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 92 Brazil clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 93 Brazil clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 94 Brazil clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 95 Brazil clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 96 Argentina clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 97 Argentina clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 98 Argentina clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 99 Argentina clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 100 Middle East & Africa clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 101 Middle East & Africa clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 102 Middle East & Africa clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 103 Middle East & Africa clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 104 South Africa clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 105 South Africa clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 106 South Africa clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 107 South Africa clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 108 Saudi Arabia clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 109 Saudi Arabia clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 110 Saudi Arabia clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 111 Saudi Arabia clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 112 UAE clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 113 UAE clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 114 UAE clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 115 UAE clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 116 Kuwait clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 117 Kuwait clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 118 Kuwait clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 119 Kuwait clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 2 Global clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 3 Global clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 4 Global clinical oncology NGS screening market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 5 Global clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 6 North America clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 7 North America clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 8 North America clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 9 North America clinical oncology NGS screening market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 10 North America clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 11 The U.S. clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 12 The U.S. clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 13 The U.S. clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 14 The U.S. clinical oncology NGS screening market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 15 The U.S. clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 16 Canada clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 17 Canada clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 18 Canada clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 19 Canada clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 20 Mexico clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 21 Mexico clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 22 Mexico clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 23 Mexico clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 24 Europe clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 25 Europe clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 26 Europe clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 27 Europe clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 28 Germany clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 29 Germany clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 30 Germany clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 31 Germany clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 32 UK clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 33 UK clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 34 UK clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 35 UK clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 36 France clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 37 France clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 38 France clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 39 France clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 40 Italy clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 41 Italy clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 42 Italy clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 43 Italy clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 44 Spain clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 45 Spain clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 46 Spain clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 47 Spain clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 48 Denmark clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 49 Denmark clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 50 Denmark clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 51 Denmark clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 52 Sweden clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 53 Sweden clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 54 Sweden clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 55 Sweden clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 56 Norway clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 57 Norway clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 58 Norway clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 59 Norway clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 60 Asia Pacific clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 61 Asia Pacific clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 62 Asia Pacific clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 63 Asia Pacific clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 64 Japan clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 65 Japan clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 66 Japan clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 67 Japan clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 68 China clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 69 China clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 70 China clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 71 China clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 72 India clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 73 India clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 74 India clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 75 India clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 76 South Korea clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 77 South Korea clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 78 South Korea clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 79 South Korea clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 80 Australia clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 81 Australia clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 82 Australia clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 83 Australia clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 84 Thailand clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 85 Thailand clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 86 Thailand clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 87 Thailand clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 88 Latin America clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 89 Latin America clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 90 Latin America clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 91 Latin America clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 92 Brazil clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 93 Brazil clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 94 Brazil clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 95 Brazil clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 96 Argentina clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 97 Argentina clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 98 Argentina clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 99 Argentina clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 100 Middle East & Africa clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 101 Middle East & Africa clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 102 Middle East & Africa clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 103 Middle East & Africa clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 104 South Africa clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 105 South Africa clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 106 South Africa clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 107 South Africa clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 108 Saudi Arabia clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 109 Saudi Arabia clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 110 Saudi Arabia clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 111 Saudi Arabia clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 112 UAE clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 113 UAE clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 114 UAE clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 115 UAE clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
TABLE 116 Kuwait clinical oncology NGS market estimates & forecasts, by technology, 2021 - 2033 (USD Million)
TABLE 117 Kuwait clinical oncology NGS market estimates & forecasts, by workflow, 2021 - 2033 (USD Million)
TABLE 118 Kuwait clinical oncology NGS market estimates & forecasts, by application, 2021 - 2033 (USD Million)
TABLE 119 Kuwait clinical oncology NGS market estimates & forecasts, by end use, 2021 - 2033 (USD Million)
List of Figures
FIG. 1 Market snapshot
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Market trends & outlook
FIG. 7 Market segmentation & scope
FIG. 8 Market restraint relevance analysis (Current & future impact)
FIG. 9 SWOT analysis, by factor (political & legal, economic and technological)
FIG. 10 Porter’s five forces analysis
FIG. 11 Strategy framework
FIG. 12 Participant categorization
FIG. 13 Clinical oncology NGS market: Technology outlook key takeaways
FIG. 14 Clinical oncology NGS market: Technology movement analysis
FIG. 15 Whole genome sequencing for clinical oncology market, 2021 - 2033 (USD Million)
FIG. 16 Whole exome sequencing for clinical oncology market, 2021 - 2033 (USD Million)
FIG. 17 Targeted sequencing and resequencing for clinical oncology market, 2021 - 2033 (USD Million)
FIG. 18 Clinical oncology NGS market: Workflow outlook key takeaways
FIG. 19 Clinical oncology NGS market: Workflow movement analysis
FIG. 20 NGS pre-sequencing for clinical oncology market, 2021 - 2033 (USD Million)
FIG. 21 NGS sequencing for clinical oncology market, 2021 - 2033 (USD Million)
FIG. 22 NGS data analysis for clinical oncology market, 2021 - 2033 (USD Million)
FIG. 23 Clinical oncology NGS market: Application outlook key takeaways
FIG. 24 Clinical oncology NGS market: Application movement analysis
FIG. 25 Screening clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 26 Sporadic cancer screening clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 27 Inherited cancer screening clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 28 Companion diagnostics clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 29 Other diagnostics clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 30 Clinical oncology NGS market: End use outlook key takeaways
FIG. 31 Clinical oncology NGS market: End use movement analysis
FIG. 32 Hospitals clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 33 Clinics clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 34 Laboratories clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 35 Regional marketplace: Key takeaway
FIG. 36 Clinical oncology NGS market: Regional outlook, 2024 & 2033
FIG. 37 North America clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 38 U.S. clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 39 Canada clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 40 Mexico clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 41 Europe clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 42 Germany clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 43 UK clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 44 France clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 45 Italy clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 46 Spain clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 47 Denmark clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 48 Sweden clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 49 Norway clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 50 Asia Pacific clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 51 Japan clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 52 China clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 53 India clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 54 South Korea clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 55 Australia clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 56 Thailand clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 57 Latin America clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 58 Brazil clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 59 Argentina clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 60 Middle East & Africa clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 61 South Africa clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 62 Saudi Arabia clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 63 UAE clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 64 Kuwait clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 65 Key companies profiled
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Market trends & outlook
FIG. 7 Market segmentation & scope
FIG. 8 Market restraint relevance analysis (Current & future impact)
FIG. 9 SWOT analysis, by factor (political & legal, economic and technological)
FIG. 10 Porter’s five forces analysis
FIG. 11 Strategy framework
FIG. 12 Participant categorization
FIG. 13 Clinical oncology NGS market: Technology outlook key takeaways
FIG. 14 Clinical oncology NGS market: Technology movement analysis
FIG. 15 Whole genome sequencing for clinical oncology market, 2021 - 2033 (USD Million)
FIG. 16 Whole exome sequencing for clinical oncology market, 2021 - 2033 (USD Million)
FIG. 17 Targeted sequencing and resequencing for clinical oncology market, 2021 - 2033 (USD Million)
FIG. 18 Clinical oncology NGS market: Workflow outlook key takeaways
FIG. 19 Clinical oncology NGS market: Workflow movement analysis
FIG. 20 NGS pre-sequencing for clinical oncology market, 2021 - 2033 (USD Million)
FIG. 21 NGS sequencing for clinical oncology market, 2021 - 2033 (USD Million)
FIG. 22 NGS data analysis for clinical oncology market, 2021 - 2033 (USD Million)
FIG. 23 Clinical oncology NGS market: Application outlook key takeaways
FIG. 24 Clinical oncology NGS market: Application movement analysis
FIG. 25 Screening clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 26 Sporadic cancer screening clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 27 Inherited cancer screening clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 28 Companion diagnostics clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 29 Other diagnostics clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 30 Clinical oncology NGS market: End use outlook key takeaways
FIG. 31 Clinical oncology NGS market: End use movement analysis
FIG. 32 Hospitals clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 33 Clinics clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 34 Laboratories clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 35 Regional marketplace: Key takeaway
FIG. 36 Clinical oncology NGS market: Regional outlook, 2024 & 2033
FIG. 37 North America clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 38 U.S. clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 39 Canada clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 40 Mexico clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 41 Europe clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 42 Germany clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 43 UK clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 44 France clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 45 Italy clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 46 Spain clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 47 Denmark clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 48 Sweden clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 49 Norway clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 50 Asia Pacific clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 51 Japan clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 52 China clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 53 India clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 54 South Korea clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 55 Australia clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 56 Thailand clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 57 Latin America clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 58 Brazil clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 59 Argentina clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 60 Middle East & Africa clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 61 South Africa clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 62 Saudi Arabia clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 63 UAE clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 64 Kuwait clinical oncology NGS market, 2021 - 2033 (USD Million)
FIG. 65 Key companies profiled
Companies Mentioned
- Illumina, Inc.
- Thermo Fisher Scientific
- F. Hoffmann-La Roche Ltd.
- Agilent Technologies
- Myriad Genetics
- Perkin Elmer
- Pacific Bioscience
- Oxford Nanopore Technologies Ltd.
- Eurofins Scientific S.E.
- Qiagen N.V.
